Publications:142
Video Visit Available
Accepting New Patients
Mount Sinai DoctorsTreats Adults
Accepting New PatientsJanice L Gabrilove, MD
Internal Medicine, Cancer (Oncology)
No Patient Experience Ratings
Book an Appointment
About Me
Janice Gabrilove, MD, FACP, is The James F. Holland Professor of Medicine at the Icahn School of Medicine at Mount Sinai. She is the Director of the Clinical Research Education Program (Certificate, Master of Science, and PhD in Clinical Research) at the Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, and Co-Director of the Patient Oriented Research Training And Leadership (PORTAL) Program, a joint MD/Master of Science in Clinical Research Program. Dr. Gabrilove is also the Associate Director of Education and Training at The Tisch Cancer Institute.
Dr. Gabrilove is a world-renowned expert on the biology of hematopoietic growth factors in normal and malignant hematopoiesis and the role of these cytokines in ameliorating disease and treatment-related myelosuppression. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy-induced myelosuppression and severe chronic neutropenia. Her initial studies demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation revolutionized the way we perform stem cell transplantation today, utilizing G-CSF mobilized PBPC.
Dr. Gabrilove has been intimately involved in the development of novel therapeutics for fostering leukemic cell maturation, and received patents for two Food and Drug Administration (FDA) approved drugs for the treatment of Acute Promyelocytic Leukemia. She has served on the FDA Advisory Committee for the Approval of Biologics.
An elected member of the American Society for Clinical Investigation (ASCI), Dr. Gabrilove has received numerous awards in recognition of excellence in education, teaching and clinical care. Actively engaged in career development, she has mentored more than 38 residents, Hematology/Oncology fellows, and junior faculty.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Research Topics
Bioinformatics, Biophysics, Computational Biology, Computer Simulation, Drug Design and Discovery, Integrins, Mathematical and Computational Biology, Membrane Proteins/Channels, Protein Complexes, Protein Structure/Function, Signal Transduction, Theoretical Biology, Theoretical Biophysics
About Me
Janice Gabrilove, MD, FACP, is The James F. Holland Professor of Medicine at the Icahn School of Medicine at Mount Sinai. She is the Director of the Clinical Research Education Program (Certificate, Master of Science, and PhD in Clinical Research) at the Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, and Co-Director of the Patient Oriented Research Training And Leadership (PORTAL) Program, a joint MD/Master of Science in Clinical Research Program. Dr. Gabrilove is also the Associate Director of Education and Training at The Tisch Cancer Institute.
Dr. Gabrilove is a world-renowned expert on the biology of hematopoietic growth factors in normal and malignant hematopoiesis and the role of these cytokines in ameliorating disease and treatment-related myelosuppression. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy-induced myelosuppression and severe chronic neutropenia. Her initial studies demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation revolutionized the way we perform stem cell transplantation today, utilizing G-CSF mobilized PBPC.
Dr. Gabrilove has been intimately involved in the development of novel therapeutics for fostering leukemic cell maturation, and received patents for two Food and Drug Administration (FDA) approved drugs for the treatment of Acute Promyelocytic Leukemia. She has served on the FDA Advisory Committee for the Approval of Biologics.
An elected member of the American Society for Clinical Investigation (ASCI), Dr. Gabrilove has received numerous awards in recognition of excellence in education, teaching and clinical care. Actively engaged in career development, she has mentored more than 38 residents, Hematology/Oncology fellows, and junior faculty.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Research Topics
Bioinformatics, Biophysics, Computational Biology, Computer Simulation, Drug Design and Discovery, Integrins, Mathematical and Computational Biology, Membrane Proteins/Channels, Protein Complexes, Protein Structure/Function, Signal Transduction, Theoretical Biology, Theoretical Biophysics
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Biopsy
- Chemotherapy
- Hematologic Malignancies
- Hodgkin's Disease
- Hodgkin's Lymphoma
- Leukemia
Show More
Education
MD, Icahn School of Medicine at Mount Sinai
Residency, Internal Medicine
New York Presbyterian Hospital/Columbia University
Fellowship, Hematology & Oncology
Memorial Sloan-Kettering Cancer Center
Certifications
American Board of Internal Medicine
Awards
2009
Best Doctors
New York Magazine
Research
Dr. Gabrilove is a pioneer in the development of our understanding of the biology of hematopoietic growth factors and their clinical utility in promoting hematopoietic reconstitution. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy induced myelosuppression and severe chronic neutropenia. Her initial studies also demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation has revolutionized the way in which we perform marrow transplantation today, which is conducted almost exclusively utilizing G-CSF mobilized PBPC. This laboratory is currently investigating: the development of novel therapeutic strategies in CLL; and the role of arsenicals as experimental therapeutics to induce apoptosis.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Intraoperative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization. Andrew B. Leibowitz, Christy Adamsky, Janice Gabrilove, Daniel M. Labow. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Brian J. Druker, François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop Kantarjian, Norbert Gattermann, Michael W.N. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice L. Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John Shepherd, Giuseppe Saglio, Alois Gratwohl, Johan L. Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson. New England Journal of Medicine
- An analysis of current neutropenia therapies, including pegfilgrastim. Janice L. Gabrilove. Clinical Cornerstone
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Gabrilove during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Memorial Sloan-Kettering Cancer Center
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Gabrilove during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Memorial Sloan-Kettering Cancer Center
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.